Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

(MedPage Today) — ORLANDO — Patients with hemophilia B continued to experience low annualized bleeding rates and stable endogenous factor IX expression 5 years after a single infusion of etranacogene dezaparvovec (Hemgenix), the final analysis…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118932

Author :

Publish date : 2025-12-10 17:18:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

FDA Opens Safety Review of Injectable RSV Drugs Approved for Babies and Toddlers

Related Posts

FDA Opens Safety Review of Injectable RSV Drugs Approved for Babies and Toddlers

ACIP Chair’s Hot Mic; Don’t Deny COVID Vax Deaths; Abortion Drug Study Stalled

Inside the wild experiments physicists would do with zero limits

Phase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast Cancer

AI Model Improves Prediction of Early and Late Breast Cancer Recurrence

COVID Vax Death Probe Expands; Eggs Recalled; Med School Enrollment Up

Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

FDA Opens Safety Review of Injectable RSV Drugs Approved for Babies and Toddlers

ACIP Chair’s Hot Mic; Don’t Deny COVID Vax Deaths; Abortion Drug Study Stalled

Inside the wild experiments physicists would do with zero limits

Phase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast Cancer

AI Model Improves Prediction of Early and Late Breast Cancer Recurrence

COVID Vax Death Probe Expands; Eggs Recalled; Med School Enrollment Up

Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer

Categories

Archives